Fluoroquinolone prophylaxis utility during chemoradiation induced severe neutropenin in patients with acute leukemia, with fluoroquinolone resistance high prevalence, in a reference hospital in Mexico City;Utilidad de la profilaxis con fluoroquinolonas durante la neutropenia grave inducida por quimioterapia en pacientes con leucemia aguda, en un hospital de referencia de la Ciudad de México con alta prevalencia de resistencia a fluoroquinolonas

Revista de Investigacion Clinica

Volumn 58, Issue 6, 2006, Pages 547-554

  Ugarte Torres, Alejandra ^a   Villasis Keever, Angelina ^a   Hernández Bribiesca, María Elena ^a   Crespo Solis, Erick ^b   Ruiz Palacios, Guillermo M ^a   Sifuentes Osornio, José ^a   Ponce de León Garduño, Alfredo ^a  

^a Departamento de Infectología   (Mexico)

^b INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

Antimicrobial resistance; Neutropenia; Prophylaxis

Indexed keywords

ANTINEOPLASTIC AGENT; CIPROFLOXACIN; FLUCONAZOLE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ADOLESCENT; ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIUM ISOLATE; BACTERIUM ISOLATION; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; ESCHERICHIA COLI; FEBRILE NEUTROPENIA; FEMALE; GRAM NEGATIVE BACTERIUM; GRANULOCYTOPENIA; HODGKIN DISEASE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MEXICO; MORTALITY; MULTIMODALITY CANCER THERAPY; NEUTROPENIA; NONHUMAN; PREVALENCE; SURVIVAL TIME; TREATMENT DURATION;

ADULT; AGED; BACTEREMIA; DRUG RESISTANCE, MICROBIAL; FEMALE; FLUOROQUINOLONES; HOSPITALS; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MEXICO; NEUTROPENIA; PREVALENCE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; URBAN POPULATION;

EID: 33947398402     PISSN: 00348376     EISSN: 00348376     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Kerr K. The prophylaxis of bacterial infections in neutropenic patients. J Antimicrob Chemotherapy 1999; 44: 587-91.
2. Klastersky J, Paesman M, Rubenstein EB, et al. The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000; 18: 3030-51.
3. Tattersshal M, Spiers A, Darrell J. Initial therapy with combination of five antibiotics in febrile patients with leukaemia and neutropaenia. Lancet 1972; 299: 162-6.
4. Del Favero A, Menichetti F. The new fluorinated quinolones for antimicrobial prophylaxis in neutropenic cancer patients. Eur J Cancer 1993; 29A (Suppl. 1): 2-6.
5. Cruciani M, Rampazzo R, Malena M, et al. Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a metaanalysis. Clin Infect Dis 1996; 4: 795-805.
6. Cruciani M, Malena M, Bosco O, Nardi S, Serpelloni G, Mengoli C. Reappraisal with meta-analysis of the addition of gram-positive prophylaxis to fluoroquinolone in neutropenic patients. J Clin Oncol 2003; 21: 4127-37.
7. Engels EA, Lau J, Barza M. Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. J Clin Oncol 1998; 16:1179-87.
8. Dejace P, Klastersky J. Emergence of resistance as a consequence of antimicrobial prophylaxis in immunocompromised patients. Scand J Infect Dis (Supp].) 1986: 49: 165-71.
9. Kanamaru A, Tatsumi Y. Microbiological data for patients with febrile neutropenia. Clin Infect Dis 2004; 39 (Suppl. 1): S7-S10.
10. Hughes WT, Armstrong D, Bodey GP, et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dig 2002; 34: 730-51.
11. Kato M, Bautista A, Rolon M, et al. Increasing trend of antimicrobial drug-resistance in organisms causing bacteremia at a tertiary-care hospital: 1995 to 2000. Rev Invest Clin 2003; 55: 600-5.
12. NCCLC. Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically. Approved standard. Sixth edition. 2004, volume 23, number 2. M7-A6, p. M100-S14.
13. van der Waaij D, Berghuis JM. Determination of the colonization resistance of the digestive tract of individual mice. J Hyg (Lond) 1974, 72: 379-87.
14. Rozemberg-Arska M, Dekker AW, Verhoef J. Ciprofloxacin for selective descontamination of the alimentary tract in patients with acute leukemia during remission induction treatment: the effect on fecal flora. J Infect Dig 1985, 152: 104-7.
15. Maschmeyer G, Haralamble E, Gaus W, et al. Ciprofloxacin and norfloxacin for selective descontamination in patients with severe granulocytopenia. Infection 1988; 2: 98-104.
16. Van der Auwera P, Gerain J. Use of the quinolones in the prophylaxis and treatment of granulocytopenic immunocompromised cancer patients. Drugs 1993; 45 (Suppl 3:) 81-90.
17. Del Favero A, Menichetti F. The new fluorinated quinolones for antimicrobial prophylaxis in neutropenic cancer patients. Eur J Cancer 1993; 29A (Suppl. 1): 2-6
18. Cromer M, Akard L, Blanck, Allen S. Infection prevention in severly mielosuppressed patients: a comparison between ciprofloxacin and a regimen of selective antibiotic modulation of intestinal flora. Am M Med 1994; 4:35-41.
19. D' Antonio D, Piccolomini R, Iacone A, et al. Comparison of ciprofloxacin, ofloxacin and pefloxacin for the prevention of bacterial infection in neutropenic patients with haematological malignancies. J Antimicrob Chemother 1994; 4: 837-44.
20. Bar W, Welling GW, Kurrie E. Effects of selective oral antimicrobial prophylaxis and systemic antibiotics on the fecal flora and beta-aspartyglycine concentration in patients with acute leukemia. AP-MIS 1989; 8: 705-14.
21. Brodsky AL, Minissale CJ, Melero MJ, Sanchez Avalos JC. Prophylaxis with fluoroquinolones in patients with neutropenia. Medicina (B Aires) 1993; 3: 401-7.
22. Imrie K, Prince H, Couture F, Brandwein J, Keating A. Effect of antimicrobial prophylaxis on hematopoietic recovery following autologous bone marrow transplantation: ciprofloxacin versus co-trimoxazole. Bone Marrow Transpl 1995; 15: 267-70.
23. Catarralá J, Fernandez-Sevilla A, Tubau F, Callis M, Gudiol F. Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who received prophylactic norfloxacin. Clin Infect Dis 1995; 20: 557-60.
24. Peña C, Albareda JM, Pallarés R, Pujol M, Tubau F, Aniza J. Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in blood stream infections. Antimicrob Agents Chemother 1995; 39: 520-4.
25. Kern WV, Klose K, Jellen-Ritter AS, et al. Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia. Eur J Clin Microbiol Infect Dis 2005; 24: 111-8.
26. Gómez L, Garau J, Estrada C, et al. Ciprofloxacin prophylaxis in patients with acute leukemia and granulocytopenia in an area with high prevalence of ciprofloxacin-resistant Escherichia coli. Cancer 2003; 97: 419-24.
27. Martino R, Subira M, Altés A, López R, Sureda A, Domingo-Albo A, Pericas R, S. Brunet. Effect of discontinuing prophylaxis with norfloxacin in patients with hematologic malignancies and severe neutropenia. A matched case-control study of the effect on infectious morbidity. Acta Haematol 1998; 99: 206-11.
28. Reuter S, Kern WV, Sigge A, Döhner H, Maine R, Kern P, von Baum H. Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematological malignancies. Clin Infect Dis 2005; 40: 1087-93.
29. Rubinstein E, Potgieter P, Davey P, Norrby SR. The use of fluoroquinolonas in neutropenic patients-analysis of adverse effects. J Antimicrob Chemother 1994; 34: 7-19.
30. Bucaneve G, Micozzi A, Menichetti F, Martino P, et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Eng J Med 2005; 353: 977-87.
31. Cullen M, Neil, S, Billingham L, Gaunt C, et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 2005; 335: 988-98.